News from myr pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 04, 2020, 04:51 ET MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX®

MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic...


Jun 10, 2020, 08:07 ET MYR Pharmaceuticals has incorporated its first European subsidiary in France

MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic...


May 29, 2020, 12:34 ET MYR Pharmaceuticals receives positive CHMP opinion for HEPCLUDEX® (bulevirtide), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infections

MYR Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a...


Nov 01, 2019, 18:33 ET MYR Pharmaceuticals Announces Multiple Presentations at the AASLD Meeting 2019 in Boston.

MYR Pharmaceuticals today announced the presentation of a number of results on bulevirtide at the upcoming meeting of American Association for the...


Apr 04, 2019, 11:28 ET MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.

MYR Pharmaceuticals today announced that the final results of the MYR203 study of bulevirtide (Myrcludex), MYR's first-in-class entry inhibitor for...